Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ambarella Inc (AMBA) Tanking After Citron Research Report; Buy Or Steer Clear?

Page 1 of 2

Last week, short-selling firm Citron Research released a report on Ambarella Inc (NASDAQ:AMBA) that wasn’t exactly flattering to say the least. In it, the firm called Ambarella a “ridiculous” stock and  set a 12-month price target of just $60, and an 18-month price target of $40 on the stock of the semiconductor processing solutions company, which was trading as high as $126 last week. The report cited commoditization risks, a lack of innovation, and Ambarella Inc (NASDAQ:AMBA)’s “parabolic frenzy” for its scathing conclusion about the company. After the report, Ambarella’s stock plummeted heavily. On Friday, Ambaralla was down by 6.9%. On Monday it tumbled another 19.08% to $96.58. Over 8.9 million shares were traded, which clearly bested the stock’s three-month daily average trading volume of 2.23 million. The reversal came after a meteoric rise since the chip-maker’s IPO in 2012, during which time shares increased 21-fold from their mere $6 offering price. Ambarella has greatly benefited from its partnership with GoPro Inc (NASDAQ:GPRO), for whom it supplies the chips for its wearable cameras. However, as Citron’s report stated, the valuation for Ambarella had it trading at double the projected adjusted 2018 earnings multiple of the sports action camera company, whose coattails it’s being perceived as riding.

Leonard Zhukovsky /

Leonard Zhukovsky /

Apart from the latest report and its effects on Ambarella Inc (NASDAQ:AMBA), we must also take into account hedge funds’ positions in the stock. By the end of the first quarter, 23 of the hedge funds we track at Insider Monkey had long positions in AMBA. There were 17 hedge funds in our database which had AMBA positions at the end of the previous quarter. This is a 35% change showing positive hedge fund sentiment.

We at Insider Monkey pay close attention to hedge funds’ positions in companies, especially in small-caps, because our research has proven that tracking hedge funds’ top bets is fruitful. We analyzed the historical stock picks of these investors and our research revealed that the small-cap picks of these funds performed far better than their large-cap picks, which is where most of their money is invested and why their performance as a whole has been poor. A portfolio of the 15 most popular small-cap stocks among funds outperformed the S&P 500 Total Return Index by 95 basis points per month between 1999 and 2012 in backtesting. The exceptional results of this strategy got even better in forward testing after the strategy went live at the end of August 2012, returning more than 142% and beating the market by more than 83 percentage points since then, and by 4.6 percentage points in the first quarter of this year (see the details).

Another powerful metric to consider is insider trading, which research has also shown to be a great piggybacking method for investors, when it comes specifically to tracking insider purchases (correlation is much lower when it comes to insider sales). When it comes to insider sentiment, CFO George Laplante sold 4,184 shares of the company at $117.60 on June 16, while VP of Marketing Christopher Day sold over 7,000 shares through five separate transactions in June. There have been no recorded insider purchases of the company’s stock.

Let’s move on to a study of hedge fund activity in Ambarella Inc (NASDAQ:AMBA).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!